|ViroStat was founded in 1985 by Dr. Douglas McAllister to provide infectious disease antibody tools to researchers and manufacturers. These include the areas of virology, bacteriology and parasitology. The company offers more than 500 infectious disease reagents including their MONOTOPE™ monoclonal antibodies, OMNITOPE™ polyclonal antibodies and numerous recombinant antigens.|
New Product Information
Antigen Detection of COVID-19 Variants
Variants of this virus have evolved due to mutations in the Spike protein. While most antigen detection tests target the nucleocapsid of the virus with the use of antibody pairs. The nucleocapsid is relatively conserved in comparison to the Spike protein.
However mutations also do occur in the nucleocapsid. If the antibody pair used for detection now fails to bind to this antigen because of a mutation then this could result in a false negative test result.
All of ViroStat’s COVID-19 monoclonal antibodies have been validated for their reactivity with the nucleocapsids of the most common variants currently circulating including: UK B.1.1.7, South Africa B.1.351 and Brazil P.1. Thus ensuring that the variants will be detected with these antibodies.
|3851||nucleoprotein of SARS & COVID-19||Mouse||100 µg||Datasheet1|
|3861||nucleoprotein of SARS & COVID-19||Mouse||100 µg|
|3862||nucleoprotein of SARS & COVID-19||Mouse||100 µg|
|3863||nucleoprotein of SARS & COVID-19||Mouse||100 µg|
|3864||nucleoprotein of SARS & COVID-19||Mouse||100 µg|
Detection of Gram Positive BacteriaThere are medical conditions where rapid detection of Gram Positive bacteria is critical. An example of this is sepsis where time is of the essence. Most Gram Positive bacteria possess a cell wall polymer of lipoteichoic acid (LTA). LTA can be shed from growing bacteria and is also present on the intact bacterium itself.
ViroStat has just released a new set of monoclonal antibodies to LTA. These antibody pairs can be used to detect both free LTA as well as cell wall LTA of intact bacteria.
These new antibodies detect the LTA of many Gram Positive bacteria including: Staph aureus, Staph epidermidis, Strep pneumoniae, Strep pyogenes, Bacillus cereus, Bacillus subtilis, Enterococcus faecalis and Listeria species.
These new antibody pairs represent powerful tools for assay development for bacterial detection.
|3801||lipoteichoic acid||Mouse||100 µg||Datasheet|
|3811||lipoteichoic acid||Mouse||100 µg|
|3802||lipoteichoic acid||Mouse||100 µg|
|3803||lipoteichoic acid||Mouse||100 µg|
|3804||lipoteichoic acid||Mouse||100 µg|
NEW Antibodies for COVID-19 Virus Detection
The nucleocapsid of COVID-19 virus is ideal for antigen detection for two major reasons:
1) It is produced abundantly in infected cells
2) it is a highly conserved protein and therefore not prone to mutation.
The cytoplasm of infected cells fills with the nucleocapsid antigen. These cells can be collected on a NP swab and added to a specimen buffer to lyse and release this antigen for detection by immunoassay.
ViroStat has developed and just released a set of new monoclonal antibodies to the nucleocapsid of the COVID-19 virus. These final 5 antibodies were selected from an initial group of 60 based upon highest binding affinity and best ELISA pairing for detection of native viral antigen. Datasheet
Astrovirus Monoclonal Antibodies from VirostatAstrovirus is a relatively newly discovered family of non-enveloped RNA viruses that cause gastroenteritis in animals and humans. Young children and the elderly are most susceptible due to underdeveloped or waning immune systems respectively. Symptoms include vomiting and diarrhea which can lead to dehydration. The virus can be detected in feces via PCR and immunoassay.
ViroStat has released a set of new Monoclonal Antibodies to Astrovirus. These antibodies are specific to the major capsid protein of the virus and form pairs for detecting this antigen. Datasheet
Please contact us for any inquiries, questions, or information requests.
Tokyo Future Style, Inc.